Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241108 | 0.87 | RAB9A (0.60) | ALDH1A1RAB9ANPC1TSHRSMN1; SMN2 | |
| SCHEMBL1269593 | 0.87 | RAB9A (0.60) | ALDH1A1RAB9ANPC1TSHRSMN1; SMN2 | |
| SCHEMBL7624466 | 0.84 | ALDH1A1 (1.00) | ALDH1A1RAB9ANPC1LTC4SSMN1; SMN2 | |
| SCHEMBL29355043 | 0.84 | ALDH1A1 (1.00) | ALDH1A1RAB9ANPC1LTC4SSMN1; SMN2 | |
| SCHEMBL6901269 | 0.83 | ALDH1A1 (0.53) | ALDH1A1RAB9ANPC1EPHX1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6906101 | 0.83 | ALDH1A1 (0.70) | ALDH1A1RAB9ANPC1LTC4STSHR | |
| SCHEMBL1932276 | 0.82 | MAPK1 (0.64) | ALDH1A1RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL30366839 | 0.81 | TSHR (0.71) | ALDH1A1RAB9ANPC1TSHRSMN1; SMN2 | |
| SCHEMBL26686613 | 0.80 | MAPK1 (0.52) | ALDH1A1RAB9ANPC1EPHX1SMN1; SMN2 | |
| SCHEMBL6901408 | 0.79 | NPC1 (0.51) | ALDH1A1RAB9ANPC1EPHX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116418-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB | 2002-09-19 | — | — | US | disclosed |
| US-6376492-B1 | GUANIDINE DERIVATIVES | MEDIVIR AB (SE) | 2002-04-23 | — | — | US | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | disclosed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | POLRMT, POLM, POLR1E | ALDH1A1 2484/4885RAB9A 3313/4885NPC1 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.